BioLife Solutions vs ICU Medical
Add, change or remove companies; up to four.
The short version
- ICU Medical is the larger business, with $2.2B of revenue in fiscal 2025 against $96.2M for BioLife Solutions, about 23 times as much.
- BioLife Solutions grew revenue faster (28.9%, against β6.3%).
- ICU Medical kept more of each dollar of sales as operating profit (1.9% operating margin, against β17.3%).
- BioLife Solutions turned more of its sales into free cash flow (11.1% FCF margin, against 4.1%).
- ICU Medical earned a higher return on the capital invested in it (0.7%, against β4.8%).
| Latest fiscal year | BLFS Β· FY25 | ICUI Β· FY25 |
|---|---|---|
| Size | ||
| Market cap | β | $4.2B |
| Revenue | $96.2M | $2.2B |
| Free cash flow | $10.6M | $91.8M |
| Net income | β$4.6M | $0.7M |
| Growth | ||
| Revenue growth | 28.9% | β6.3% |
| 5-year growth | 14.9% | 11.9% |
| Share count change | 5.6% | 2.1% |
| Profitability | ||
| Gross margin | 64.6% | 36.8% |
| Operating margin | β17.3% | 1.9% |
| Net margin | β4.8% | 0.0% |
| FCF margin | 11.1% | 4.1% |
| Return on capital | β4.8% | 0.7% |
| Return on equity | β1.3% | 0.0% |
| Balance sheet | ||
| Net debt | β$83.9M | $983M |
| Net debt / EBITDA | β | 4.0x |
| Dividends and buybacks | $0.0M | $8.8M |
| Valuation & quality | ||
| P/E | β | 140.0x |
| Piotroski F-score | 6 | 6 |
Revenue
FY16
BLFS $8.2M
ICUI $379M
FY17
BLFS $11.0M
ICUI $1.3B
FY18
BLFS $19.7M
ICUI $1.4B
FY19
BLFS $27.4M
ICUI $1.3B
FY20
BLFS $48.1M
ICUI $1.3B
FY21
BLFS $119M
ICUI $1.3B
FY22
BLFS $76.2M
ICUI $2.3B
FY23
BLFS $68.0M
ICUI $2.3B
FY24
BLFS $74.6M
ICUI $2.4B
FY25
BLFS $96.2M
ICUI $2.2B
BLFS
ICUI
Operating margin
FY16
BLFS β59.0%
ICUI 21.9%
FY17
BLFS β9.6%
ICUI β1.0%
FY18
BLFS 18.6%
ICUI 2.1%
FY19
BLFS β0.8%
ICUI 8.5%
FY20
BLFS β13.0%
ICUI 7.7%
FY21
BLFS β29.5%
ICUI 9.4%
FY22
BLFS β7.8%
ICUI β1.9%
FY23
BLFS β25.3%
ICUI 1.0%
FY24
BLFS β6.0%
ICUI 1.8%
FY25
BLFS β17.3%
ICUI 1.9%
BLFS
ICUI
Free cash flow
FY16
BLFS β$4.5M
ICUI $66.6M
FY17
BLFS $0.5M
ICUI $79.9M
FY18
BLFS $1.9M
ICUI $67.5M
FY19
BLFS $0.5M
ICUI $4.6M
FY20
BLFS $4.7M
ICUI $131M
FY21
BLFS β$13.0M
ICUI $199M
FY22
BLFS β$18.9M
ICUI β$152M
FY23
BLFS β$18.9M
ICUI $82.3M
FY24
BLFS $5.2M
ICUI $125M
FY25
BLFS $10.6M
ICUI $91.8M
BLFS
ICUI
Return on capital
FY16
BLFS β
ICUI β
FY17
BLFS β
ICUI β
FY18
BLFS β
ICUI β
FY19
BLFS β
ICUI β
FY20
BLFS β6.5%
ICUI β
FY21
BLFS β10.5%
ICUI β
FY22
BLFS β1.3%
ICUI β
FY23
BLFS β4.2%
ICUI 0.5%
FY24
BLFS β1.2%
ICUI 1.0%
FY25
BLFS β4.8%
ICUI 0.7%
BLFS
ICUI
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.